ESMO Congress Updates - Baseline Assessment - Germany

Return to Enrollment Page

OVERVIEW

We will explore the most recent evidence-based recommendations, guidelines, and clinical trial presentations of HR+ BC, ADCs, immunotherapy, and Parp-inibithors on management of patients with BC. We will identify the therapeutic algorithm for patients with HER2 low breast cancer.

FACULTY

Francesco Pantano MD, PHD

Campus Biomedico Roma,
Rome, Italy

Francesco Pantano is a medical oncologist and associate professor at the Campus Bio-Medico University of Rome. He obtained a degree in medicine and surgery, a specialization in medical oncology and a research doctorate in osteo-oncological pathology at the Campus Bio-Medico University of Rome. From 2012 to 2014 he carried out research abroad, as a PhD student and PostDoc, at INSERM in Lyon where he focused on the role of alpha5 integrin in the processes of bone metastasis in pre-clinical models of breast cancer.

He is currently co-head of the Translational Oncology Laboratory at the Campus Bio-Medico University where he coordinates various research projects aimed at identifying new biomarkers that do not predict the efficacy of immunotherapies and new potential therapeutic targets in advanced solid tumors. He also holds the role of Head of the Osteoncology Center and contact person for the "Breast Unit" for the Oncology UOC.

LEARNING OBJECTIVES

1.
Assess the efficacy of new target therapy options in the management of patients with HR + early and metastatic BC with and implications for team-based and shared decision-making globally
2.
Apply the most recent evidence-based recommendations when managing patients with HR+ and BRCAm+ BC, based on specific patient and tumor characteristics
3.
Discuss the most recent evidence -based recommendations, guidelines, and clinical trial presentations on the role of treatment optimization for HR+/HER2- breast cancer